Last updated: July 10, 2026

Application No. 19/351,985

Untitled Application

Unknown

Filed

1600

Priority

Feb 05, 2014 — provisional 61/936,019 +17 more

Examiner

ROZOF, TIMOTHY R

Art Unit

1625

Tech Center

Merck Sharp & Dohme LLC

Assignee

Merck Sharp & Dohme LLC

OA Round

1 (Non-Final)

Interview Optional

— +24.0% interview lift. Examiner has a relatively high allowance rate (73%); +24.0% interview lift. A written response may suffice.

Based on 960 resolved cases, 2023–2026

Examiner Intelligence

ROZOF, TIMOTHY R View full profile →

Grants 73% — above average

Career Allowance Rate

697 granted / 960 resolved

+12.6% vs TC avg

Strong +24% interview lift

Without

With

+24.0%

Interview Lift

resolved cases with interview

Fast prosecutor

2y 0m

Avg Prosecution

46 currently pending

Career history

992

Total Applications

across all art units

Statute-Specific Performance

§101

1.0%

-39.0% vs TC avg

§103

24.0%

-16.0% vs TC avg

§102

28.0%

-12.0% vs TC avg

§112

21.4%

-18.6% vs TC avg

Black line = Tech Center average estimate • Based on career data from 960 resolved cases

Prosecution Timeline

1600

Application Filed

Precedent Cases

Applications granted by this same examiner with similar technology

18/263,546

Patent 12661359

THERAPEUTIC COMBINATIONS OF ROSUVASTATIN AND RESMETIROM FOR THE TREATMENT OF LIVER DISORDERS OR LIPID DISORDERS

2y 10m to grant Granted Jun 23, 2026

18/270,351

Patent 12662462

SALTS OF PYRIDINYLMETHYLENEPIPERIDINE DERIVATIVES AND USES THEREOF

2y 12m to grant Granted Jun 23, 2026

18/257,540

Patent 12649744

N-(PYRIDIN-2-YL)-6,7,8,9-TETRAHYDRO-5H-5,8-EPIMINOCYCLOHEPTA[C]PYRIDINE-10-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS GPR65 MODULATORS FOR THE TREATMENT OF CANCER

2y 12m to grant Granted Jun 09, 2026

18/282,872

Patent 12649748

WEE1 INHIBITOR AND USE THEREOF

2y 8m to grant Granted Jun 09, 2026

18/767,083

Patent 12649720

CRYSTAL FORMS OF 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE

1y 11m to grant Granted Jun 09, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

73%

Grant Probability

97%

With Interview (+24.0%)

2y 0m

Median Time to Grant

Low

PTA Risk

Based on 960 resolved cases by this examiner. Grant probability derived from career allowance rate.